Competitor Landscape: HIV

Researchmoz added Most up-to-date research on "Competitor Landscape: HIV" to its huge collection of research reports. An insight on the important factors and trends influencing the market.
Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the HIV market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharmas view of the disease landscape
- Landscape Updates: Order of Entry analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved products lifecycle management initiatives; Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019

Get a Sample PDF at: https://www.researchmoz.us/enquiry.php?type=S&repid=1978218

Key Highlights

- Doravirine (approved in the US in Aug 2018) provides a tolerable NNRTI option with a high barrier to resistance, and is expected be used as part of multi-pill triple combinations where it may replace older NNRTIs
- If approved, ibalizumab would be the first biologic and first long-acting HIV drug in the EU, and would provide an option for patients with multidrug-resistant HIV infection which represents a population with a high unmet need
- While Frontier Biotech received China approval for albuvirtide for the treatment of HIV in Jun 2018, its FDA approved IND for a Phase II trial of albuvirtide + 3BNC117 is the first indication of clinical activity in the US.

Scope

- The briefing is based on Sociable Pharmas analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/competitor-landscape-hiv-report.html/toc

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

For More Reports Visit @ http://marketresearchlatestreports.blogspot.com/

Human Immunodeficiency Virus (HIV) Market 2017 - Global Industry Size, Shares, Trends, Growth, Analysis and Forecast 2021

Researchmoz added Most up-to-date research on "Global Human Immunodeficiency Virus (HIV) Market: Industry Analysis & Outlook (2017-2021)" to its huge collection of research reports.

HIV (Human immunodeficiency virus) is a retrovirus which causes HIV infection and attacks the CD-4 cells (T-cells) in the immune system of human body. HIV reduces the number of T-cells in the body and makes the immune system vulnerable to life-threatening infections and cancers. An infected person cannot get rid of this virus properly but its effects can be reduced with the treatment.

HIV does not get spread easily into human. Only certain body fluids of an infected person can transmit HIV into others. HIV never gets transmitted through casual contacts like handshakes, sharing food or water. It has certain transmission ways including blood transmission of an infected person to non-infected person, exchange of body fluids like semen, pre-seminal or vaginal fluids during unprotected physical contacts and from a mother to child during pregnancy or breastfeeding.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1129610

HIV therapeutics market is likely to witness a growth with increasing demand for single tablet regimens and growth of HIV diagnostic market is expected to be driven by increasing technological advancements in diagnosis tests.

Middle East and Africa are the major contributors to the global HIV market supported by increased prevalence of HIV due to rising drug abuse and unprotected physical contacts among adolescents. Asia-Pacific is likely to experience further growth of HIV market due to recent development in HIV treatments.

The global HIV market is expected to grow in future due to decreasing HIV related death rates, low awareness of HIV transmission and government initiatives to promote HIV treatment. Key trends of this market include progressing HIV drug under pipeline, increasing adoption of STR and Development of technologically advanced diagnostic products. However, there are some factors which can hinder growth of the market including decreasing global HIV funds, social stigma and discrimination and treatment failures.

The report “Global HIV Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S along with the global market. The report profiles players of the market including Johnson & Johnson, Merck and Co., Gilead and GlaxoSmithKline Plc.

Table of Content

1. Overview
1.1 HIV

2. Global HIV Market
2.1 Global HIV Therapeutics Market Forecast by Value
2.2 Global HIV Therapeutics Market by Drug Class
2.2.1 Global Integrase Inhibitor Market Forecast by Value
2.2.2 Global NNRTI Market Forecast by Value
2.2.3 Global Protease Inhibitor Market Forecast by Value
2.3 HIV Therapeutics Market by Brand
2.4 HIV Diagnostic Market Forecast by Value
2.5 HIV Diagnostic Market by Type
2.5.1 Global CD4 Tests Market Forecast by Value
2.5.2 Global Viral Load Tests Market Forecast by Value
2.6 HIV Patient Population
2.7 HIV Patient Population Forecast
2.8 HIV Patient Population by Region
2.9 New HIV Infected Population
2.10 New HIV Infected Population Forecast
2.11 New HIV Infected Population by Region
2.12 HIV Patient Population on ART
2.13 HIV Patient Population on ART Forecast
2.14 HIV Patient Population on ART by Region

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-human-immunodeficiency-virus-hiv-market-industry-analysis-outlook-20172021-report.html/toc

3. Regional HIV Market
3.1 The U.S. HIV Patient Population Forecast
3.2 The U.S. Diagnosed HIV Population Forecast
3.3 The U.S HIV Population on ART Forecast

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Decreasing HIV related Death Rates
4.1.2 Low Awareness of HIV Transmission
4.1.3 Government Initiative to Promote HIV Treatment
4.2 Key Trends
4.2.1 Progressing HIV Drugs Under Pipeline
4.2.2 Increasing Adoption of STR
4.2.3 Development of Technologically Advanced Diagnostic Products
4.3 Challenges
4.3.1 Decreasing Global HIV Funds
4.3.2 Social Stigma and Discrimination
4.3.3 Treatment Failures

5. Competition
5.1 Market Share by Company
5.2 Revenue Comparison

Continue...

HIV/AIDS Therapeutics Industry Key Trends, Size, Growth, Shares And Forecast Research Report 2018

Researchmoz added Most up-to-date research on "HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth" to its huge collection of research reports.

GBI Research, a leading business intelligence provider, has released its latest research, “HIV/AIDS Therapeutics Market to 2018 Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth”. The report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV/AIDS therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV/AIDS therapeutics market. The report analyzes the market for HIV/AIDS therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report provides branded and generics segmentation in the therapeutic landscape segment. In addition, it analyzes the HIV/AIDS therapeutics market in India, China and Australia. The report discusses the global pipeline for all the HIV/AIDS molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research found that the HIV/AIDS therapeutics market in the top seven markets was valued at $13.5 billion in 2011, increasing at a Compound Annual Growth Rate (CAGR) of 12.5% during the 2004–2011 historic period. The market is projected to witness growth of 7% during the 2011–2018 forecast period to reach $21.8 billion. The growth is primarily driven by the increase in the use of single dose multi-class combination drugs such as Atripla, Complera. With the recent launch of Stribild (previously known as Quad), the multi-class combination drugs would drive the market.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=149606

Scope

- Annualized market data for the HIV/AIDS therapeutics market from 2004 to 2011, forecast forward to 2018.
- Analysis of the HIV/AIDS therapeutics market in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan.
- Analysis of the HIV/AIDS therapeutics market in India, China and Australia.
- Market characterization of the HIV/AIDS therapeutics market including market size, annual cost of treatment, and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. Key companies studied in this report are Gilead Sciences, Bristol-Myers Squibb, GlaxoSmithKline, Abbott Laboratories, Johnson & Johnson, Merck, and Roche.
- Key M&A activities and licensing agreements that have taken place between 2008 and up to June 2012 in the global HIV/AIDS therapeutics market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and HIV/AIDS therapeutics market segments poised for strong growth.
- Create a more tailored country strategy through the understanding of key drivers and barriers of the global HIV/AIDS therapeutics market.
- Develop key strategic initiatives by understanding the key focus areas and top selling products of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1 Table of Contents 51.1 List of Tables 7
1.2 List of Figures 9

2 HIV/AIDS Therapeutics Market to 2018 - Introduction 11

3 HIV/AIDS Therapeutics Market to 2018 - Overview 12
3.1 Disease Overview 12
3.1.1 Diagnostic Tests for HIV 13
3.2 WHO Guidelines for HIV/AIDS Treatment 14
3.2.1 WHO Clinical Staging of HIV Disease in Adults and Adolescents 15
3.2.2 Summary of Changes to the WHO’s Guidelines on Initiation of ART based on CD4 Count and Clinical Staging 16
3.2.3 Summary of Changes to WHO’s Guidelines on First-line Antiretrovirals 17
3.2.4 Summary of Changes to the WHO’s Guidelines on Second-line Antiretrovirals 18
3.3 Drugs Classes Used in HIV/AIDS Treatment 19
3.3.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors 19
3.3.2 Non-nucleoside Reverse Transcriptase Inhibitors 20
3.3.3 Protease Inhibitors 20
3.3.4 Fusion Inhibitors 21
3.3.5 CCR5 Co-receptor Antagonist 21
3.3.6 Integrase Inhibitors 21
3.3.7 Multi-class Combination Drugs 22
3.4 Key Marketed Products 23
3.4.1 Atripla 23
3.4.2 Truvada 25
3.4.3 Reyataz 27
3.4.4 Sustiva 28
3.4.5 Isentress 29
3.5 Advancements in HIV/AIDS Vaccine Research 30

4 HIV/AIDS Therapeutics Market to 2018 - Market Characterization and Forecast 31
4.1 Introduction 31
4.2 Revenue Forecast 32
4.2.1 Market Share by Drug Class (%), 2011 33
4.3 Branded Versus Generics Market Share (%), 2011 34
4.4 Market Share by Company (%), 2011 35
4.5 Annual Cost of Therapy 36
4.6 Treatment Usage Pattern 38
4.6.1 Diseased Population 39
4.6.2 Diagnosed Population 39
4.6.3 Prescription Population 39
4.7 HIV/AIDS Therapeutics Market - Drivers and Restraints 40
4.7.1 HIV/AIDS Therapeutics Market - Drivers 40
4.7.2 Market Restraints 42

5 HIV/AIDS Therapeutics Market to 2018 - The US 45
5.1 Market Overview 45
5.2 Revenue Forecast 45
5.3 Annual Cost of Therapy 46
5.4 Treatment Usage Pattern 47
5.4.1 Diseased Population 48
5.4.2 Diagnosed Population 48
5.4.3 Prescription Population 48

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=149606